Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Basmisanil?

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial

Awakn Life Sciences Corp. (NEO: AWKN) (OTCMKTS: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has

September 6, 2023

Medicare Advantage’s 33 million club

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday.

February 20, 2024

Atezolizumab by F. Hoffmann-La Roche for Glioblastoma Multiforme (GBM): Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.